company background image
XENE

Xenon Pharmaceuticals NasdaqGM:XENE Stock Report

Last Price

US$37.89

Market Cap

US$2.4b

7D

-1.5%

1Y

105.4%

Updated

12 Aug, 2022

Data

Company Financials +
XENE fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

XENE Stock Overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Xenon Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xenon Pharmaceuticals
Historical stock prices
Current Share PriceUS$37.89
52 Week HighUS$41.39
52 Week LowUS$14.65
Beta1.54
1 Month Change14.54%
3 Month Change27.23%
1 Year Change105.37%
3 Year Change332.53%
5 Year Change1,184.41%
Change since IPO260.86%

Recent News & Updates

Jun 13
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

How far off is Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) from its intrinsic value? Using the most recent financial...

Shareholder Returns

XENEUS BiotechsUS Market
7D-1.5%1.2%3.2%
1Y105.4%-21.7%-10.1%

Return vs Industry: XENE exceeded the US Biotechs industry which returned -23% over the past year.

Return vs Market: XENE exceeded the US Market which returned -11.7% over the past year.

Price Volatility

Is XENE's price volatile compared to industry and market?
XENE volatility
XENE Average Weekly Movement8.5%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: XENE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: XENE's weekly volatility has decreased from 17% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996151Ian Mortimerhttps://www.xenon-pharma.com

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials.

Xenon Pharmaceuticals Inc. Fundamentals Summary

How do Xenon Pharmaceuticals's earnings and revenue compare to its market cap?
XENE fundamental statistics
Market CapUS$2.36b
Earnings (TTM)-US$91.84m
Revenue (TTM)US$21.16m

111.5x

P/S Ratio

-25.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XENE income statement (TTM)
RevenueUS$21.16m
Cost of RevenueUS$82.28m
Gross Profit-US$61.12m
Other ExpensesUS$30.72m
Earnings-US$91.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.47
Gross Margin-288.81%
Net Profit Margin-433.95%
Debt/Equity Ratio0%

How did XENE perform over the long term?

See historical performance and comparison